These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30178044)

  • 1. Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program.
    Jones LC; Dhruva SS; Redberg RF
    JAMA Intern Med; 2018 Oct; 178(10):1418-1420. PubMed ID: 30178044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence strength in FDA premarket approval of cardiovascular devices.
    Kong DF; Hasselblad V; Krucoff MW
    JAMA; 2010 Apr; 303(16):1599-600; author reply 1600-1. PubMed ID: 20424248
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA perspective on clinical trial design for cardiovascular devices.
    Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
    Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
    [No Abstract]   [Full Text] [Related]  

  • 4. Inclusion of comparative effectiveness data in high-risk cardiovascular device studies at the time of premarket approval.
    Chen CE; Dhruva SS; Redberg RF
    JAMA; 2012 Nov; 308(17):1740-2. PubMed ID: 23117769
    [No Abstract]   [Full Text] [Related]  

  • 5. Endovascular brachytherapy: the FDA's perspective.
    Ryan TA
    Int J Radiat Oncol Biol Phys; 1996 Nov; 36(4):992-3. PubMed ID: 8960543
    [No Abstract]   [Full Text] [Related]  

  • 6. Spinal devices in the United States-investigational device exemption trials and premarket approval of class III devices.
    Golish SR; Reed ML
    Spine J; 2017 Jan; 17(1):150-157. PubMed ID: 27737804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Let the spin begin. Greater transparency urged for device trials.
    Becker C
    Mod Healthc; 2005 Mar; 35(11):33. PubMed ID: 15794228
    [No Abstract]   [Full Text] [Related]  

  • 8. When to conduct a clinical trial.
    Boutrand JP
    Med Device Technol; 2004 Oct; 15(8):28-31. PubMed ID: 16225271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007.
    Kramer DB; Mallis E; Zuckerman BD; Zimmerman BA; Maisel WH
    Am J Ther; 2010; 17(1):2-7. PubMed ID: 20038828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in the approval process for interventional devices in Europe and USA: IN MEDIO STAT VIRTUS.
    Di Mario C
    EuroIntervention; 2011 Mar; 6(8):913, 915-7. PubMed ID: 21330236
    [No Abstract]   [Full Text] [Related]  

  • 11. Benefit-Risk Assessments at the US Food and Drug Administration: Finding the Balance.
    Califf RM
    JAMA; 2017 Feb; 317(7):693-694. PubMed ID: 28114599
    [No Abstract]   [Full Text] [Related]  

  • 12. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices.
    Dhruva SS; Bero LA; Redberg RF
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):165-71. PubMed ID: 21364127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful recruitment for medical device clinical studies.
    Donawa M
    Med Device Technol; 2004 Oct; 15(8):25-7. PubMed ID: 16225270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based medicine and drug-eluting stents.
    O'Dwyer J
    Med Device Technol; 2004 May; 15(4):34-7. PubMed ID: 15303564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical device regulatory landscape: the imperative of finding balance.
    Kaplan AV; Williams DO
    Circ Cardiovasc Interv; 2012 Feb; 5(1):2-5. PubMed ID: 22337999
    [No Abstract]   [Full Text] [Related]  

  • 16. Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013: A Cross-sectional Study.
    Phillips AT; Rathi VK; Ross JS
    JAMA Intern Med; 2016 Apr; 176(4):551-2. PubMed ID: 26902933
    [No Abstract]   [Full Text] [Related]  

  • 17. The proposed rule for U.S. clinical trial registration and results submission.
    Zarin DA; Tse T; Sheehan J
    N Engl J Med; 2015 Jan; 372(2):174-80. PubMed ID: 25539444
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA's role in medical device clinical studies of human subjects.
    Saviola J
    J Neural Eng; 2005 Mar; 2(1):S1-4. PubMed ID: 15876645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress versus precision: challenges in clinical trial design for left ventricular assist devices.
    Parides MK; Moskowitz AJ; Ascheim DD; Rose EA; Gelijns AC
    Ann Thorac Surg; 2006 Sep; 82(3):1140-6. PubMed ID: 16928569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Town Hall at CRT 2017: Current status and future endeavors in cardiovascular devices.
    Buchanan KD; Alraies MC; Waksman R
    Cardiovasc Revasc Med; 2017 Jun; 18(4):308-311. PubMed ID: 28577795
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.